MMP9 Recombinant Rabbit mAb (SDT-1591-56)
MMP9 Recombinant Rabbit mAb (SDT-1591-56)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | MMP9 |
| Synonyms | Matrix metalloproteinase-9; MMP-9 |
| Immunogen | Recombinant Protein |
| Accession | P14780 |
| Clone Number | SDT-1591-56 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | No cross-reactivity against MMP2, MMP3, MMP7, MMP8, MMP13 |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
Matrix metalloproteinase-9 (MMP-9), also known as gelatinase B, is a 92 kDa zinc-dependent endopeptidase and a member of the matrix metalloproteinase (MMP) family. It is synthesized and secreted as an inactive zymogen, which contains an N-terminal propeptide domain, a zinc-containing catalytic domain with three fibronectin type II repeats, and a C-terminal hemopexin-like domain. MMP-9 plays a crucial role in the degradation of various extracellular matrix (ECM) components, such as collagen, fibronectin, and laminin, and is involved in tissue remodeling. It is also associated with multiple pathological processes, including cancer, chronic inflammation, and cardiovascular diseases. MMP9 has been found to be associated with numerous pathological processes, including cancer, arthritis, placental malaria, immunologic and cardiovascular diseases, and it has been explored as a potential biomarker and therapeutic target.
Picture
Picture
Paired Recommendations
